Feds Call Halt to Johnson & Johnson COVID-19 Vaccine Rollout After ‘Extremely Rare’ Blood Clot Cases

Source: FiercePharma

After drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials are calling for an immediate pause to the rollout, according to a FiercePharma report.

Since the vaccine’s late February emergency use authorization in the U.S., nearly 7 million people have received the shot. Six recipients of the vaccine—all women between 18 and 48—were diagnosed with rare blood clots afterward, the FDA says. One died and one has been hospitalized, The New York Times reports. The FDA on Tuesday said it’s “recommending a pause in the use of this vaccine out of an abundance of caution.”

Read the full article.

Related Content